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Abstract
Background
Prostate-specific antigen (PSA) testing for prostate cancer is controversial. There are unre-
solved tensions and disagreements amongst experts, and clinical guidelines conflict. This
both reflects and generates significant uncertainty about the appropriateness of screening.
Little is known about general practitioners’ (GPs’) perspectives and experiences in relation
to PSA testing of asymptomatic men. In this paper we asked the following questions: (1)
What are the primary sources of uncertainty as described by GPs in the context of PSA test-
ing? (2) How do GPs experience and respond to different sources of uncertainty?
Methods
This was a qualitative study that explored general practitioners’ current approaches to, and
reasoning about, PSA testing of asymptomatic men. We draw on accounts generated from
interviews with 69 general practitioners located in Australia (n = 40) and the United Kingdom
(n = 29). The interviews were conducted in 2013–2014. Data were analysed using grounded
theory methods. Uncertainty in PSA testing was identified as a core issue.
Findings
Australian GPs reported experiencing substantially more uncertainty than UK GPs. This
seemed partly explainable by notable differences in conditions of practice between the two
countries. Using Han et al’s taxonomy of uncertainty as an initial framework, we first outline
the different sources of uncertainty GPs (mostly Australian) described encountering in rela-
tion to prostate cancer screening and what the uncertainty was about. We then suggest an
extension to Han et al’s taxonomy based on our analysis of data relating to the varied ways
that GPs manage uncertainties in the context of PSA testing. We outline three broad strate-
gies: (1) taking charge of uncertainty; (2) engaging others in managing uncertainty; and (3)
transferring the responsibility for reducing or managing some uncertainties to other parties.
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Conclusion
Our analysis suggests some GPs experienced uncertainties associated with ambiguous
guidance and the complexities of their situation as professionals with responsibilities to
patients as considerably burdensome. This raises important questions about responsibility
for uncertainty. In Australia in particular they feel insufficiently supported by the health care
system to practice in ways that are recognisably consistent with ‘evidence based’ profes-
sional standards and appropriate for patients. More work is needed to clarify under what cir-
cumstances and how uncertainty should be communicated. Closer attention to different
types and aspects of the uncertainty construct could be useful.
Introduction
Prostate-specific antigen (PSA) testing for prostate cancer is controversial. There are unre-
solved tensions and disagreements amongst experts, and clinical guidelines conflict. This both
reflects and generates significant uncertainty about the appropriateness of testing, especially in
asymptomatic men. The United States Preventive Services Taskforce (USPSTF) recommends
physicians should not offer or order PSA screening unless they are prepared to engage in
shared decision making (SDM) that enables an informed choice by the patient; this includes
providing information about the associated uncertainties [1]. The Royal Australian College of
General Practitioners (RACGP) advises GPs not to raise the issue of PSA testing unless men
specifically ask, in which case they should provide full information regarding the benefits,
risks, and uncertainties (about benefits and risks) [2]. The UK’s National Screening Committee
(UK NSC) policy similarly does not recommend universal screening for prostate cancer.
Instead there is an informed choice program in place where men who request PSA testing can
have it following detailed information exchange to aid shared decision making.
Primary care clinicians advise on and are gatekeepers to the PSA test. In practice, they vary
in what they disclose to patients about the uncertainty and controversy that surrounds it. Rec-
ognition of uncertainty may in general be ethically preferable, facilitating more completely-
informed consent [3] and promoting realistic patient expectations about medical care [4,5].
However, research from the US and UK suggests communication of uncertainties with patients
in the context of PSA testing is infrequent and complex [6–8].
Uncertainty is a common but under-researched issue in general practice and clinical deci-
sion making [9,10]. Some research about communication in various clinical settings indicates
that doctors can be reluctant to disclose uncertainty, preferring to present the appearance of
certainty to their patients [11,12], and to avoid being judged as inadequate or ineffective [13].
There are different findings (and suggestions about the implications of) communicating uncer-
tainty. Communicating uncertainty can have a negative effect on patients, including heighten-
ing perception of risk, causing unnecessary worry [14], and decreasing ability to make
decisions about care [15]. In contrast, other research suggests honest expressions of uncertainty
may improve the doctor patient relationship [13], facilitating trust [11], therapeutic effective-
ness [16] and patient confidence [10], and decreasing patient interest and participation in med-
ical screening [6,17,18].
Studies investigating doctors’ experiences of uncertainty, specifically in the context of PSA
testing, are scarce. The experience of uncertainty is a challenging phenomenon to explore [14];
yet it is central to much of medical practice. Some argue that tolerance of uncertainty is an
essential dimension of professional competence [19]. Others have suggested that changing
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professional and public attitudes towards medical error and uncertainty is key to reducing
overdiagnosis and overtreatment [20].
Han’s taxonomy of uncertainty [14] makes a valuable contribution to its conceptualisation
in health care. As shown in Box 1 (modified), the taxonomy has three dimensions: sources of
uncertainty (where uncertainty comes from), issues of uncertainty (what uncertainty is about),
and locus of uncertainty (who is uncertain).
In this paper we first report on clinician perspectives and experiences of uncertainty in rela-
tion to PSA testing using Han’s framework. We then add to Han’s taxonomy an outline of the
strategies that GPs use to manage uncertainty in PSA testing.
We use data from a qualitative study that explored general practitioners’ current approaches
to, and reasoning about, PSA testing of asymptomatic men. Uncertainty in PSA testing was
identified as a core issue, and we draw on this data to address the following questions:
1. What are the primary sources of uncertainty as described by GPs in the context of PSA
testing?
2. How do GPs experience and respond to different sources of uncertainty?
Methods
Design
We applied the well-established, systematic qualitative research methodology, grounded theory
[21]. All study procedures were approved by the Cancer Institute NSW and the University of
Sydney Human Research Ethics Committee [#15245]. GPs had an opportunity to discuss the
study, and gave written consent, prior to participation.
Box 1. Han’s (2011) taxonomy of uncertainty: a summary.
Sources of uncertainty:
1. Probabilistic uncertainty generated from the indeterminacy of a phenomenon’s future
outcome, such as the probability of benefit (or harm) from a test or treatment
2. Ambiguity signifies the lack of reliability, credibility, or adequacy of information
about a phenomenon of interest, and includes imprecision (e.g. wide probability esti-
mates of benefit /harm from treatment), conflicting opinions/evidence, and lack of
information
3. Complexity is uncertainty arising from aspects of a phenomenon itself, which make it
difficult to comprehend; e.g. numerous potential outcomes from a medical test or
treatment or the existence of varied risk factors, symptoms, or signs of a given disease.
Issues of uncertainty:
1. Scientific uncertainty is disease-centred. Encompasses uncertainties about diagnosis,
prognosis, causal explanations, treatment recommendations
2. Practical uncertainty is system-centred. Applies to the structures and processes of
care (competence, quality, responsibilities)
3. Personal uncertainty is patient-centred. Psychosocial and existential issues (relation-
ships, impact on life goals)
Locus of uncertainty:
Where the uncertainty resides: with the clinician or the patient
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Participants and Setting
We recruited a sample of 69 GPs (40 Australian, 29 UK) for this study. In Australia we adver-
tised via the newsletters and email lists of GP organisations (Medicare Locals) in Sydney, in
mass and social media, and in medical journals. Rural GPs were accessed by phoning practice
managers, through colleagues, and advertising with rural Medicare Locals [22].
We included GPs from the United Kingdom to also explore PSA testing reasoning and prac-
tice in a jurisdiction with comparatively lower rates of prostate cancer screening than Australia.
We subsequently recruited 29 GPs throughout England (n = 24) and Scotland (n = 5). Our initial
sample of GPs responded to an invitation distributed by academic colleagues through profes-
sional networks. We then broadened our sample by advertising via email to members of the
Royal College of General Practitioners (RCGP), primary health care departments, university aca-
demic departments, and general practice and research mail lists. We also advertised via newslet-
ter including the Society for Academic Primary Care (SAPC) and RCGP Scotland’s eBulletin.
GPs were invited to contact KP if they were interested and willing to participate. Participat-
ing GPs were of varying ages, clinical experience, gender, and patient populations. All GPs who
expressed interest in participating were included. GPs were compensated financially for their
time.
Interviews / Data Collection
We generated data via in-depth interviews. The semi-structured interview schedule covered a
broad range of topics, including GPs’ recent clinical encounters involving PSA testing deci-
sions; communicating information; screening pathways; and overdiagnosis. The schedule was
modified between interviews, informed by the developing analysis. Uncertainty was not specifi-
cally included as a topic for discussion in the schedule; rather it was a recurring concept that
was identified during data analysis. Interviews with Australian GPs took place between March
2013 and June 2014 and with UK GPs between September and December 2014. They were all
conducted by KP, mostly by telephone and Skype, and ranged in duration from 18 to 70 min-
utes. All interviews were audio-recorded and transcribed verbatim.
Data Coding and Analysis
The analysis was led by KP, who coded the transcripts and wrote detailed memos which were
regularly reviewed and discussed by the authors in analysis meetings. A subset of transcripts
was read and coded by three authors independently; this coding was compared and discussed
to inform the development of the central concepts in the study.
A longstanding point of contention in grounded theory methodology is the relation between
the theory being produced, which is ‘grounded’ in the data collected, and existing relevant the-
ory. While early expressions of grounded theory methodology [23] strongly emphasised the
development of new theory as opposed to the testing of existing theory, contemporary main-
stream grounded theorists strongly concur that qualitative empirical work must be conducted
in the context of existing knowledge [24]. As uncertainty was identified as a core category in
our data analysis, we turned to the literature to develop a better understanding of the concept,
and identified Han’s taxonomy of uncertainty in health care [14]. This taxonomy resonated
with our interpretation of the data and suggested face validity for our early analysis of the
sources and issues of uncertainty. We used Han’s taxonomy to develop our analysis of GPs’
experiences with uncertainty and categorised our data according to the ‘sources’ and ‘issues’ of
uncertainty as described in the framework. In addition, we developed a new set of concepts
related to how GPs respond to uncertainty in PSA testing, an issue that was not included in
Han’s typology.
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Results
We identified considerable variation in GPs’ interpretation, management, and experiences of
uncertainty in terms of the source of the uncertainty they described, its impact on usual prac-
tice, and GPs perception of who should respond to uncertainty.
There seemed to be substantially more uncertainty experienced among Australian than UK
GPs, perhaps partly explainable by the notable differences in conditions of practice for PSA
testing between the two countries. The United Kingdom system is structured in several ways
likely to decrease uncertainty. There is a clear policy directive against screening asymptomatic
men for prostate cancer. There is an established norm of communicating with men who ask
about PSA testing, and a structured approach to communication including a written informa-
tion resource. In addition, referral pathways following particular test results are well-defined.
In contrast, Australian policy is not clearly defined or directive, and at the time of this study
there was no single authoritative document advising GPs how or what to communicate to men.
The lack of policy clarity seems likely to contribute to the considerable variation in GP
approaches to PSA testing [22].
Unsurprisingly, given these differences, Australian and UK GPs talked differently about
prostate cancer screening. Asymptomatic men ask about prostate cancer screening frequently
in Australian practice. Yet Australian GPs said they felt unsure about what is the “right” thing
to do about PSA testing, expressed frustration about the lack of formal guidance to direct their
practice, and many found talking with men about PSA testing a challenging experience because
of underlying uncertainty. In contrast, the majority of GPs practicing in the UK were not rou-
tinely having discussions with asymptomatic men about PSA testing. They explained that
screening men for prostate cancer is not a widely supported process, nor a common request
from patients. When men did want a PSA test, GPs favoured providing them a standard gov-
ernment-produced information leaflet, to promote informed decisions. UK GPs considered
conversations about PSA testing with asymptomatic men to be of low priority unless men
asked, and overall did not express any notable uncertainty about whether to test men or not.
As a result, there was comparatively less UK data about UK GP experiences of uncertainty. The
results described below therefore predominantly describe the Australian data. We will return
to the implications of this in the discussion.
Where Does GPs’ Uncertainty Come from andWhat Is the Uncertainty
About?
Table 1 outlines sources of GPs’ uncertainty about PSA testing. We have included Han’s defini-
tion of each source of uncertainty followed by a summary of how GPs described this type of
uncertainty manifesting in their practice.
Table 2 captures the issues of uncertainty, again presented with Han’s definition of the
issues followed by specific examples in each cell from our data. Han’s framework characterises
‘personal uncertainty’ as patient-centred. However because this study focused on the perspec-
tive of GPs, our data also includes personal uncertainty with a locus in GPs.
Our data indicate that GPs may experience a diverse range of uncertainties with respect to
PSA testing. There were important differences however, between Australian and UK GPs’
descriptions regarding what their uncertainty was about. Australian GPs’ uncertainty was
related to all three of the issues described above: scientific, practical, and personal. UK GP
experiences of uncertainty were mostly about personal issues, because (a) GPs were clear about
procedural expectations coming from government and medical bodies about PSA testing, and
scientific uncertainty was dealt with via clear guidelines and norms; and (b) UK GPs expressed
a sense that the medical profession was collectively managing the uncertainty so individual
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GPs were facing less practical uncertainty because the UK system has processes in place to help
them manage it. Thus the UK GPs’ uncertainty was predominantly patient-centred; they were
mostly concerned that when their patients sought or asked about PSA testing, they were then
burdened with uncertainty due to the uncertain nature and quality of the available information.
UK GPs did not feel uncertain themselves but worried that their ‘patients have to make well-
informed decisions and I suppose that’s where it’s such a minefield of uncertainty, it must be very
difficult for people to say that they’ve made a well-informed decision’ (UKGP26).
Below we outline strategies GPs described using to handle uncertainty in the context of PSA
testing of asymptomatic men. The information below draws primarily from the Australian
data; where observations are based on UK data this is noted.
What Strategies Do GPs Use to Manage Uncertainty?
We identified three main approaches GPs used when faced with uncertainty around PSA test-
ing, specifically about decision-making and responsibility:
Table 1. Sources of uncertainty (where is GP uncertainty coming from?).
Han’s SOURCES of uncertainty How does this taxonomy manifest in the context
of PSA testing?
PROBABILISTIC UNCERTAINTY Generated from
the indeterminacy of a phenomenon’s future
outcome, such as the probability of beneﬁt (or harm)
from a test or treatment
Several important potential outcomes may follow
from PSA testing. Early diagnosis and treatment
may decrease prostate cancer death for a small
number of men. For the majority, any mortality
beneﬁt is outweighed by risk of harm: testing and
treatment is associated with substantial harms,
including impotence, incontinence, and anxiety.
Although the probabilities of some of these
outcomes can be estimated for populations, there is
no way of knowing which individual patient will
experience which outcomes.
AMBIGUITY Lack of reliability, credibility, or
adequacy of information about a phenomenon of
interest; includes imprecision (e.g. wide probability
estimates of beneﬁt /harm from treatment),
conﬂicting opinions/evidence, and lack of information
The PSA test performs poorly as a screening tool. It
is known that some screen-detected prostate
cancers are more aggressive than others, but the
PSA test cannot differentiate aggressive from non-
aggressive cancers. This, together with
uncertainties about treatment effects, uncertainty
about how particular patients might react to
different biomedical clinical outcomes (physically
and psycho-socially), and how patients may
respond differently to the risk of these outcomes,
means it is unclear what test results might actually
mean for each individual patient both at the point of
testing and following an abnormal test result
COMPLEXITY Arising from aspects of a
phenomenon itself, which make it difﬁcult to
comprehend; e.g. numerous potential outcomes
from a medical test or treatment or the existence of
varied risk factors, symptoms, or signs of a given
disease. Confounding, interacting factors add
complexity and complicate interpretations and
outcomes. Personal judgment and clinical
experience informs decisions.
The multiple-stage, multiple possibility sequence of
testing and treatment outlined above add
complexity to an evaluation of testing. Although the
patient descriptors used in research studies and
guidelines may seem simple (e.g. age 70+,
asymptomatic) in general practice many individual
patients are complex in ways not reﬂected in the
evidence base. This includes the presence of
comorbidities, and the difﬁculty in distinguishing
symptomatic from asymptomatic men because of
the multiplicity of causes of the symptoms
commonly associated with prostate cancer. GPs
consequently feel uncertain about how clinical
descriptors should be applied.
doi:10.1371/journal.pone.0153299.t001
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1. Sometimes GPs took charge of uncertainty, considered it a usual feature of their daily prac-
tice, and managed (at least some) uncertainties on their own
2. Sometimes GPs engaged others in managing uncertainty: they accepted some uncertainty as
a challenge and used it as an opportunity to engage the medical profession, colleagues, and
patients about how the uncertainty would be handled, to enable them to better support
patients and find shared solutions
3. Sometimes GPs sought to transfer to other parties the responsibility for reducing or manag-
ing some uncertainties.
Some GPs tended to manage all types of uncertainty about PSA testing in a relatively consis-
tent way, adopting one of the three approaches described above (i.e. some GPs usually took
charge, usually accepted and engaged, or usually transferred, although this was never absolute).
Other GPs were more variable in their approach, applying different management strategies in
Table 2. Issues of uncertainty (what is the uncertainty ABOUT?).
Han’s ISSUES of uncertainty
(what is the uncertainty about?)
Probabilistic material as a Source
of uncertainty (uncertainty
arising from the probabilistic
nature of information)
Ambiguity as a Source of
uncertainty (uncertainty arising
from the ambiguity of evidence or
expert guidance):
Complexity as a Source of
uncertainty (uncertainty arising
from the interaction of multiple
factors, some unknown):
SCIENTIFIC UNCERTAINTY
Disease-centred. Uncertainties
about diagnosis, prognosis, causal
explanations, treatment
recommendations
• GPs concerned about their
inability to predict clinical outcomes
(such as incontinence or impotence)
following testing and treatment at
the individual patient level.
Probabilities can predict aggregate
outcomes in a population, but
cannot specify their exact
distribution, or the probable severity
of potential outcomes in any given
individual.
• GPs concerned about conﬂicting
estimates for particular outcomes for
particular populations GPs uncertain
about the conclusions that should be
drawn from the evidence base for/
against screening for prostate cancer
• Interpretation of the beneﬁts and
risks of testing and treatment can
change over time and depend on
various assumptions (e.g. about
patient values and current state).
GPs concerned about evaluating
beneﬁts and risks and making
treatment decisions relating to
individual patients because of this
complexity.
PRACTICAL UNCERTAINTY
System-centred. Uncertainties
about the structures and processes
of care (competence, quality,
responsibilities)
• GPs described probabilities as
challenging to think about and apply
in individual clinical encountersGPs
unsure how urologists will work with
patients referred with a high PSA
result
• GPs uncertain about professional
practice due to disagreement
between guidelines GPs concerned
about conﬂicting guidance from
medical authority: professional
organizations and colleagues vary in
the recommendations they make
about whether or not (and under what
circumstances) to screen with
PSAGPs unclear under what
conditions they could be medically
liableGPs concerned about
inconsistent referral pathways and
advice
GPs ﬁnd communicating
probabilistic information with
speciﬁc patient types (e.g. health
illiterate, anxious, determined to
have the test) difﬁcultGPs seeing a
patient who usually consults a
different GP found this a complex
and ‘awkward’ situation in which to
practice if their testing preferences
were dissimilar to the GP they were
replacing
PERSONAL UNCERTAINTY GP/
patient-centred. Uncertainties about
psychosocial and existential issues
(relationships, impact on life goals)
GPs concerned about their inability
to predict the psychological and
existential outcomes of testing and
treatment that would be
experienced by the patient
• GPs consider what is at stake for
them as an individual clinician—
legally, psychologically, professionally
and socially—if they do or do not
testGPs uncertain about what is the
right thing to do in this context in
order to be considered a ‘good GP’
and preserve relations with their
patientsGPs concerned about
whether it is ok to change PSA
testing practice following personal
and practice experiences
• GPs concerned about their ability
to judge how ‘good’ any individual
patient’s consent/decision might be,
and what the outcomes of poor/
inaccurate judgment may mean for
them and their patientsGPs
uncertain about individual patient
tolerability of potential
consequences of their
decisionsGPs feel conﬂicted when
their own personal preferences for
testing/not testing conﬂict with
advice they provide
doi:10.1371/journal.pone.0153299.t002
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different situations. Particular sources of uncertainty also tended to elicit particular types of
responses. So GPs who tended to use different strategies to manage different types of uncertain-
ties may call upon one or all of the techniques depending on the type of uncertainty, the partic-
ular situation, and the GPs individual interpretation of it and level of tolerance.
We describe the three categories of GPs approaches below.
1. GPs taking charge of uncertainty. When we describe GPs as “taking charge of uncer-
tainty” we refer to circumstances when they recognised uncertainty, tolerated it, and accepted
it as a lasting presence in their practice. They found ways through the uncertainty for them-
selves according to their ‘own protocol’ (GP24) because ‘the scientists and the doctors cannot tell
you what’s going to happen’ (GP17). GPs taking charge had settled into ways of dealing with
some kinds of uncertainty and now just got on with it, acting confidently as lead decision-mak-
ers. It depended on the individual GP whether “taking charge” occasioned active recommenda-
tion of PSA testing or not.
Although these GPs might seek more medical information to inform further decisions fol-
lowing initial testing (e.g. actively PSA testing including repeat testing, ordering alternative
tests), this was independent of external parties: they did not describe feeling any pressure to
consult patients or recommendations before making decisions. Some GPs preferred to practice
using a ‘gut feeling sort of approach’ (GP21), because ‘nobody really knows the right answers to
any of these questions’ (GP18). For them, ‘because the science is imperfect, then personality and
medical judgement have. . .more of an important role’ (GP17). These GPs directed their PSA
testing practice according to their clinical experience.
When GPs took charge of uncertainty about testing decisions, they did not routinely discuss
uncertainty comprehensively with patients. Sometimes they believed a patient did not have the abil-
ity to cope with the complex information, and sometimes they assumed a position of making deci-
sions on behalf of patients to protect them from navigating uncertain decisions, ‘I think it’s a lot
easier for the patient to not be in that position [of making decisions grounded in uncertainty] at all’
(GP17). There were some GPs who disagreed with this as an appropriate approach; however the
GPs using it as a strategy did so to protect their patients from the uncertainty in current knowledge.
When GPs took charge, they did not perceive or experience uncertainty as burdensome:
they simply accepted that ‘it’s not clear and that’s just the way it is’ (GP20), or ‘[the PSA test is]
not perfect but it’s all we’ve got’ (GP26). One GP commented that all doctors should have the
capacity to make decisions about the evidence around PSA testing, despite its uncertainty ‘if
you think it’s too hot in the kitchen, get out. . .I have no sleepless nights worrying about missing
one, I think that’s just–just life’ (GP18). Ultimately, these GPs were comfortable acknowledging
that GPs ‘don’t have to have the answers to everything in medicine’ (GP3).
Interestingly, how to handle normal PSA test results was a source of uncertainty for some
UK GPs because all guidance following PSA testing is for symptomatic patients or abnormal
test results. UK GPs really relied on having guidelines to direct their practice. These guidelines
are, roughly: 1) don’t test; 2) if someone happens to ask, give them this information; 3) if
abnormal PSA result, refer to this hospital (clear procedure). As a result GPs said they were
uncertain about how to proceed following normal PSAs. Should they, for example, tell the man
that they could now stop worrying altogether, or that they should come back in x years? They
wanted to avoid being in this position of uncertainty so their strategy was to, wherever possible,
not test in the first place. In comparison, some Australian GPs described normal results as a
source of relief and reassurance for them and their patients, because for them, the uncertainty
of not knowing was greater than knowing a test result (abnormal of not). GPs told of how most
patients in Australia receiving PSA testing expect to be tested annually, so GPs actively test
them year-to-year in the hope of finding another normal result.
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2. GPs engaging others in managing uncertainty. In some situations, GPs were commit-
ted to engaging others in managing uncertainty about PSA testing. They took uncertainty as a
challenge, and engaged the medical profession, colleagues, and patients in their quest to make a
good decision in the context of shared uncertainty. Engaging others occurred via relationships
and communication. These GPs took it as their duty to grapple with the uncertainty and felt a
sense of responsibility to share it with the profession (usually as a member of an organisation
of GPs and specialists), and with patients: to inform them of uncertainty, ongoing debate and
lack of consensus. They expected to be supported by GP and specialist colleagues to help man-
age their own emotional and informational needs (e.g. consulting colleagues and specialists for
advice), and to in turn effectively support patients to make decisions.
Some GPs negotiating uncertainty felt more comfortable than others managing the uncer-
tainty of the ‘grey zone’ of PSA test results. In this zone (>4ng/ml,<10ng/ml) the clinical
implications of test results, and decisions about what to do, are most contested. GPs comfort-
able with managing the grey zone themselves via repeat testing or active surveillance (rather
than external referral to a specialist) had ‘no hesitation’ (GP31) to contact colleagues or special-
ists for advice and ‘reassurance. . .of what to tell the patient’ (GP5) once uncertainty moved
beyond the GPs’ ‘own level of comfort and expertise’ (GP31).
GPs who negotiated uncertainty were more inclined to talk about the uncertainty of PSA
testing with their patients. They reported telling their patients that it is not possible to be sure
about aspects of PSA testing, including probabilistic outcomes and individual prognosis, and
therefore any advice offered had some degree of underlying uncertainty. GPs told patients they
themselves don’t know what to do about PSA testing of asymptomatic men and don’t ‘pretend
to fully understand it’ (GP31), ‘so I don’t expect patients to have the capacity to–we say fully
informed, but really we’re not, so how can the patient be?’ (GP26). Yet these GPs were adamant
that regardless of the limitations of the available knowledge base, ‘the information needs to be
on the table’ (GP31).
GPs who talked to patients about the uncertainties of PSA testing said they acknowledged the
discord in professional opinion about what should be done with their patients. For many GPs
this was a source of considerable frustration: ‘every week and I’m like, for God’s sake, can someone
make a decision so I know what to do?’ (GP26). They often did not feel supported by the medical
profession: ‘It’s up to individual GPs to sort it out himself–I mean it shouldn’t happen this way,
but we’re not getting really helpful information from our so-called experts’ (GP28). The RACGP
guidelines (as outlined in the introduction) were described as unhelpful, ‘a blanket ethical state-
ment’ (GP28) and GPs said they felt ‘we’re still in a mess with what we’re actually advising men to
do. . .we don’t know what the hell we’re doing’ (GP8). Some of these GPs reported clear ideas
about how authorities should respond to support GPs and to support patients. This centred on
consensus, talking the same language, and telling GPs exactly what information they should pro-
vide patients. Some GPs did, however, recognise the difficult position authorities are in when try-
ing to produce policy in a complex situation; ‘the opinions and the spectrum. . .it just reflects that
it’s unclear and that opinion is divided depending on who you talk to’ (GP20).
For many GPs an element of discomfort with uncertainty was ever-present. GPs felt guilty
about possible negative psychosocial effects on their patients of understanding how messy and
complex the situation is; ‘the spiel that I give men about this leaves them with virtually no ability
to make a good decision. . .I don’t make things easier for people’ (GP8). GP attempts to share
their knowledge of the uncertainties and experience of being uncertain about what to do with
patients sometimes proved futile: for example if the patient wanted the GP to decide what to do
on their behalf and preferred not to be engaged in/take on the lead role in decision making.
Of the three approaches, it was the GPs engaging others in the uncertainty of PSA testing
who were most likely to experience that uncertainty as burdensome. They worked hard to
General Practitioners' Experiences of, and Responses to, Uncertainty in Prostate Cancer Screening
PLOS ONE | DOI:10.1371/journal.pone.0153299 April 21, 2016 9 / 15
make an impossible situation as good as possible. But their work to mitigate the uncertainty
was unrecognised and unrewarding; the more GPs tried to wrestle with the uncertainty, the
more uncertain the situation appeared. Yet these GPs continued to take on some uncertainty as
a challenge because doing something–engaging patients and the profession–felt appropriate
and ‘right’ to them as GPs.
3. GPs transferring uncertainty. Finally, some GPs employed strategies of “transferring”
responsibility for decision making in the face of uncertainty. They perceived uncertainty as
problematic and uncomfortable and sought out other parties to reduce their experience of
uncertainty. The external authorities could include: urologists, those researching the test, legal
authority, or the health system. One GP described this process of transferring responsibility for
decision-making as ‘handballing it to somebody else’ (GP26).
In practice, GPs in this category were not likely to repeat PSA test results that returned in
the grey zone, rather preferring to refer those patients immediately to specialists to make deci-
sions about the next stage of management. In fact a subset of GPs were committed to immedi-
ate referral regardless of what the PSA test result was: ‘even though it’s [PSA] still well within
the normal range for their age—I just think that’s a specialist’s [urology] decision, not mine’
(GP26). For GPs, having urology as a backup meant they could regard uncertain PSA results as
‘not my problem, quite frankly’ (GP25).
Some GPs engaged in active PSA testing as a strategy for managing their uncertainty, partic-
ularly about potential legal ramifications of not testing; ‘I would probably still send him for the
test because I’d be worried somebody would sue me if I didn’t’ (GP22). One GP said that when
in a position of not knowing what to do ‘I think medico-legal comes into that. . .you’re more
defensive in your acting’ (GP34). This subgroup of GPs looked to legal authority to protect
them and justify their practice, and perceived medico-legal obligations influenced their practice
particularly when they felt uncertain about what to do.
Some GPs left decision making entirely up to the individual patient to deal with; ‘so I say
well it’s your decision and if you want to have it, you can. If you don’t want to worry about it,
that’s ok with me too. So I let them decide basically’ (GP21). A number of practices in Australia
had implemented their own policy: a recall system whereby patients would be automatically
notified when due for a PSA test with an accompanying pathology form. In these instances,
GPs minimised repeated engagement with the uncertainties of PSA testing and personal
responsibility for patient decision-making. By automating the process they effectively trans-
ferred responsibility for follow-up to a practice management system, and their patients would
in turn choose how to respond to the automated invite.
Those GPs whose default-practice was to transfer responsibility had worked out a way of
practicing which relieved them of the burden of advising and making practice decisions based
on uncertain foundations (at least until their next consultation involving a PSA test). This risk-
averse approach–transferring uncertainty to external authority as soon as possible–was per-
ceived by GPs as a way to save patients from being burdened by GP uncertainty and meant the
GP did not have to engage with what they considered an unresolvable situation.
How Do GPs Respond to Different Sources of Uncertainty?
Probabilistic uncertainty was identified as a major source of uncertainty by the GPs, yet they
tended to speak of it as being more tolerable than uncertainties arising from ambiguity and
complexity. Overall, GPs accepted responsibility for probabilistic uncertainty and shared their
knowledge about it; it was not as common for GPs to attempt to transfer responsibility for this
source of uncertainty. Many GPs described handling probabilistic uncertainty reasonably com-
fortably on their own. They saw it as central to the GP role and to clinical judgment, which
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necessarily involves interpreting scientific evidence and probabilities. Individuals or organisa-
tions were not blamed or held directly responsible for probabilistic uncertainty. GPs described
probabilistic uncertainty as challenging (e.g. indeterminate medical outcomes), but had mostly
found a relatively settled way of dealing with it because they had few alternatives.
The two other types of uncertainty invoked different responses: uncertainty arising from
ambiguity—for example, varied recommendations—and complexity—the vagueness of clinical
descriptors, or the difficulty in judging patient understanding. Many GPs preferred to negotiate
or transfer responsibility for these uncertainties. For example, a GP experiencing uncertainty
in a testing decision might tell the patient about discordant recommendations to justify their
uncertainty and immediately refer to specialists for further opinion. Some GPs appeared to
hold that responsibility for ambiguity or complexity should be collective and others should be
involved in negotiating decisions, or they preferred to transfer those decisions to specialists.
Ambiguity and complexity commonly led to practical issues for GPs arising from this uncer-
tainty–how to engage in ‘good’ practice and appropriate communication based on complex evi-
dence and ambiguous guidance. Ambiguity and complexity were also a foundation for GPs’
sense of personal burden, as some GPs expressed anxiety about their capacity to make ‘good’
decisions without good evidence, and ability to judge what level of information was suitable to
support consent. Theoretically these sources of uncertainty could be modified or improved
with system change (for example, consistent recommendations, established consent protocols)
but GPs felt limited in their capacity to make changes at the clinical level.
Discussion
GPs described experiencing considerable and, at times, burdensome uncertainty in the context
of PSA testing of asymptomatic men for prostate cancer. Locating and describing sources or
types of uncertainty (Table 1) as per Han is important in this context because the various types
of uncertainty produced different issues (Table 2), which GPs responded to and managed
using distinct strategies (our 3 strategies outlined above).
Sources, Issues, and Management of Uncertainty
GPs in our study appeared to manage uncertainty arising from probabilistic information with
reasonable confidence when compared to the other sources of uncertainty. One possible expla-
nation for this finding is that GPs are familiar with probabilities and are trained to interpret
and manage probabilistic information in the clinical setting. Numerous resources are available
presenting probabilistic and statistical information in multiple formats (numerically, graphi-
cally) to assist GPs and to support the decision making capacity of their patients. While proba-
bilistic uncertainty is particularly challenging in relation to PSA testing and cannot be readily
resolved with leaflets or information sheets, we propose that such resources ‘normalise’ the
probabilistic uncertainty inherent to this context. It is possible that GPs feel more comfortable
taking charge or engaging with others about probabilistic uncertainty because they are better
able to get a handle on the uncertainty they are dealing with because it is an ongoing and famil-
iar type of uncertainty. Probabilistic information about outcomes is also the typical kind of
information assumed to be shared in processes of shared decision-making.
It is clear from our results that uncertainty from ambiguity on the other hand was extremely
frustrating for GPs; GPs were uncertain about guidance from medical authorities and were
unclear of their clinical and legal obligations. These uncertainties are grounded in ambiguity,
which, as the decision psychology literature has shown, people generally prefer to avoid (e.g.
[25]. Ambiguity is more directly related to uncertainties about what to do in practice than
probabilistic uncertainty, and perhaps leaves more scope for GPs to take a “wrong” course of
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action. Aspects of ambiguity in this context are potentially modifiable, which could reduce
some uncertainty for GPs. For example, clearer and more consistent expert guidance may
assist. Yet even if more ‘certainty’ was implemented at the system-level via clear guidelines or
consistent advice from authoritative sources, clinicians will inevitably still experience some per-
sonal uncertainty stemming from the complexity of this information, and because of diverse
GP and patient value systems in the clinical context (e.g. questioning appropriateness of
recommendations).
Complexity was also experienced as particularly uncomfortable for GPs; some GPs described
feeling uncertain about their own clinical judgment. Complexity is essentially a source of uncer-
tainty amenable to individual value judgment, interpretation, and assumptions. It is therefore dif-
ficult to offer training or advice to GPs about ideal management of complexity uncertainty in
relation to PSA testing. While clearer expert opinion may lessen ambiguity, GPs are left to deal
with complexity at the clinical level with the individual patient. Our data from UKGPs illustrates
that even with system-level guidance and clear ‘best practice’ formulations, GPs continue to expe-
rience personal uncertainty because every patient and consultation involving PSA testing is dif-
ferent and involves difficult value judgments. Clinicians will invariably face ongoing uncertainty
about the nature of medical evidence and individual and distributive health care [26].
The Burden of Uncertainty
Ordering PSA tests for screening purposes is paradoxical in relation to uncertainty. Testing is a
response to uncertainty: an attempt to better predict a man’s risk of developing prostate cancer.
Yet while PSA testing aims to reduce uncertainty, the characteristics of the test when used as a
screening tool mean that it tends to introduce more scientific, practical, and personal uncer-
tainty than it eliminates. Faced with a PSA test result, the clinical significance of which is
intrinsically uncertain, some GPs actively tried to lessen uncertainty by looking to guidelines
on which to base decisions, or by sharing their knowledge with patients. However these strate-
gies also tended to compound uncertainty, piling up knowledge about the uncertainties regard-
ing outcomes, and GPs felt further burdened as a result. This is the great paradox of the PSA. If
GPs chase certainty via more and more testing and investigation, this may create more uncer-
tainty. Testing can undoubtedly create certainty for some GPs and patients at the individual
level, but it comes at a cost of lots of uncertainty, including GPs’ top line uncertainty about
using the PSA test at all. This, as our research has demonstrated, is what inflicts considerable
burden on GPs: because they have burdened patients with information which cannot provide
any clear answer, because their efforts to locate certainty have gone unrewarded, and because
of remaining uncertainty about what counts as good practice.
Uncertainty and the associated struggle is not just a burden to be borne by individual practi-
tioners. There is an expectation that GPs will practice in line with professional standards and
evidence-based medicine. If GPs are expected to act according to these standards, it would be
reasonable to suppose that the health care system might owe GPs some reciprocal supports to
make it possible for them to do so.
Ethical Considerations
There are judgments to be made about how best to involve men in PSA testing decisions. Our
data touches on uncertainties about whether, when, and in what forms communicating about
uncertainty is considered appropriate. Communicating uncertainty is not simply about proba-
bilities; ambiguity and complexity are also key sources of GP uncertainty and subsequent bur-
den. Any attempt to guide communication about uncertainty in PSA testing practice may be
more effective if it addresses all three sources of uncertainty.
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Ethical questions remain in relation to presenting uncertainty to patients who wish to avoid
making medical decisions; coping with uncertainty is known to be a source of substantial stress
and anxiety for many patients (e.g. [27]. Manson and O’Neill argue that a trusting and respon-
sive relationship might be more valued by patients than detailed information exchange [28].
Perhaps in some situations, a “taking charge” approach, whereby GPs call on their professional
experience and apply ‘rules of thumb’ to direct their practice might be appropriate, while in
more complex situations, GPs may need to discuss and reach agreement with others regarding
how decisions based on uncertainty will be allocated and resolved.
More work is needed to clarify under what circumstances uncertainty should be communi-
cated to patients, and if so what aspect of the uncertainty construct should be addressed. Para-
scandola et al argue that respectful interaction with patients requires disclosure about
uncertainty even when it is not offered to gain consent or in the service of patient decision
making; as long as patients understand the general decision making context [29]. Ideally, doc-
tors need to feel supported in their dealings with uncertainty. Research suggests that when doc-
tors are comfortable with uncertainty and collaborate with patients in their medical care,
patient trust and satisfaction are high [29].
Limitations
This analysis was inductive rather than commencing with research questions about uncer-
tainty. Further research could test our findings and explore the impacts of uncertainty in more
depth.
Conclusions
These important aspects of uncertainty require further and specific investigation, including the
potential implications of clinician uncertainty for cost and quality of health care [30].
This study is a first step in mapping how clinicians practice under conditions of uncertainty.
Our unique findings identified what doctors actually do in response to the different types of
uncertainty encountered. These results have practical value: the GPs in our study responded to
the various types of uncertainty and their associated issues differently. It seems likely that GPs
and their patients will benefit from greater acknowledgment by the profession of specific
sources of uncertainty and their unique implications, and in particular the often-neglected
uncertainty arising from ambiguity or complexity. Achieving this would be an essential step in
promoting GP engagement with uncertainty, and ultimately patient involvement in better
informed decisions about PSA testing for prostate cancer.
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